{{medical}}
{{chembox
| ImageFile = Buformin.svg
| ImageFile_Ref = {{chemboximage|correct|??}}
| ImageName = Skeletal formula of buformin
| ImageFile1 = Buformin-3D-balls.png
| ImageFile1_Ref = {{chemboximage|correct|??}}
| ImageName1 = Skeletal formula of buformin
| OtherNames = ''N''-Butylimidocarbonimidic diamide{{Citation needed|date=July 2012}}
| Section1 = {{chembox 识别
|  CASNo = 692-13-7
|  CASNo_Ref = {{cascite|correct|??}}
|  PubChem = 2468
|  PubChem_Ref = {{pubchemcite|correct|pubchem}}
|  ChemSpiderID = 2374
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
|  UNII = W2115E9C7B
|  UNII_Ref = {{fdacite|correct|FDA}}
|  EINECS = 211-726-4
|  DrugBank = DB04830
|  KEGG = D00595
|  KEGG_Ref = {{keggcite|correct|kegg}}
|  MeSHName = Buformin
|  ChEMBL = 39736
|  ChEMBL_Ref = {{ebicite|correct|EBI}}
|  ATCCode_prefix = A10
|  ATCCode_suffix = BA03
|  SMILES = CCCCn:c(:[nH]):[nH]:c(:[nH]):[nH2]
|  SMILES1 = CCCCNC(=N)NC(N)=N
|  StdInChI = 1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
|  StdInChIKey = XSEUMFJMFFMCIU-UHFFFAOYSA-N
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}
| Section2 = {{chembox 性质
|  C = 6
|  H = 15
|  N = 5
|  LogP = -1.2<ref>[http://books.google.com/books?id=DeX7jgInYFMC&pg=PA344&lpg=PA344&dq=buformin+log+p&source=bl&ots=kD4N7zz11L&sig=oPJougME5QRVRkurbrWvZYJJ8oU&hl=en&sa=X&ei=xJkEUMu1A-S56wGXsMz4CA&ved=0CDEQ6AEwAA#v=onepage&q=buformin%20log%20p&f=false F. Macdonald. Dictionary of pharmacological agents: Volumes 1-2 - Page 344, 1997]</ref>
}}
| Section3 = {{chembox 药理
|  AdminRoutes = 口服
|  Excretion = 肾脏
}}
| Section4 = {{chembox 相关
|  OtherCpds = {{unbulleted list|[[Carmustine|Carmustine]]|[[Methylarginine|Methylarginine]]|[[Asymmetric_dimethylarginine|Asymmetric dimethylarginine]]|[[Acecarbromal|Acecarbromal]]}}
}}
}}
'''丁二胍'''，又名丁双胍，药品名'''丁福明'''，是一种口服降血糖药，於1957年被合成<ref>Seymour L. Shapiro et al. Salts Of N-Amylbiguanide. US Patent number: 2961377; Filing date: Aug 5, 1957; Issue date: 1960</ref>，主要用于二型[[糖尿病|糖尿病]]的治疗，与[[二甲双胍|二甲双胍]]、[[苯乙双胍|苯乙双胍]]同属于双胍类口服降血糖药。

==化学性质==
盐酸丁二胍是白色或黄色，无味，[[晶体|晶体]]粉末，嚐起來有微酸苦味。

[[熔点|熔点]] 174 到 177°C，为[[强碱|强碱]]，可溶于[[水|水]]、[[甲醇|甲醇]]、[[乙醇|乙醇]]，不溶于[[氯仿|氯仿]]和[[醚类|醚类]]<ref>Jacker HJ. [New Pharmacologic Products. 2. Buformin For Oral Therapy Of Diabetes]. Pharm Prax. 1964;10:247-9.</ref><ref>Eustace George Coverly Clarke, Judith Berle, Pharmaceutical Society of Great Britain. Dept. of Pharmaceutical Sciences. Isolation and identification of drugs in pharmaceuticals, body fluids and post-mortem material, Volume 1. Pharmaceutical Press 1974, p226</ref>。

[[分配系数|分配系数]] (log P 辛醇-水) -1.20E+00；水溶性在25°C为 7.46E+05 毫克/升。[[蒸汽压|蒸汽压]]于25°C 为 1.64E-04 毫米汞柱  (估计值)。

==作用机理==
盐酸丁二胍能够延迟肠胃途径的糖吸收，增加胰岛素敏感性和细胞的糖摄入，并且抑制肝糖合成。盐酸丁二胍和其他双胍类口服降糖药一样，不是以直接降血糖为主要作用机理，而是对抗血糖水平过高。服用不会产生低血糖的现象，但能够有效降低糖尿病人的空腹与餐后血糖<ref>Enrique Ravina, Hugo Kubinyi. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. Wiley. 2011 p 215</ref>。

==剂量==
日常给药剂量为 150–300 毫克 口服<ref>Gustav Kuschinsky, Heinz Lüllmann. Textbook of pharmacology. Academic Press p 225, 1973</ref>。

==副作用与用药禁忌==
常见副作用为食欲匮乏，恶心，腹泻，口中有金属味和体重减轻。有糖尿病昏迷，[[酮酸中毒|酮酸中毒]]，严重感染或创伤者禁用。

==毒性==
盐酸丁二胍由于可能导致乳酸堆积的機率增加，而在一些国家被下市。目前在[[罗马尼亚|罗马尼亚]]、[[匈牙利|匈牙利]]、[[台湾|台湾]]和[[日本|日本]]仍作为[[处方药|处方药]]被应用。<ref>Hankó B, Tukarcs E, Kumli P, Vincze Z. Antidiabetic drug utilization in Hungary. Pharm World Sci. 2005 Jun;27(3):263-5.</ref><ref>Hankó BZ, Reszegi CA, Kumli P, Vincze Z. [Practice of antidiabetic therapy in Hungary]. Acta Pharm Hung. 2005;75(2):77-86.</ref><ref>Jerry L. Schlesser, Gale Research Inc. Drugs available abroad. Derwent Publications, Ltd - 1990 p28</ref><ref name=Verdonck>{{cite journal | author = Verdonck L, Sangster B, van Heijst A, de Groot G, Maes R | title = Buformin concentrations in a case of fatal lactic acidosis | journal = Diabetologia | volume = 20 | issue = 1 | pages = 45–6 | year = 1981 | pmid = 7202882 | doi = 10.1007/BF01789112}}</ref><ref>Chou CH, Cheng CL, Huang CC. 
A validated HPLC method with ultraviolet detection for the determination of buformin in plasma. Biomed Chromatogr. 2004 May;18(4):254-8.</ref><ref>[http://www.medicalnewstoday.com/articles/61752.php Takeda Announces Submission Of Application For Additional Indication Of Actos In Japan; Concomitant Therapy With Biguanides For Type 2 Diabetes. Medical News Today. 28 Jan 2007]</ref>乳酸堆积症一般只在盐酸丁二胍血浆浓度超过的 0.60 微克/毫升的病人中发生，在肾功能正常的患者中十分罕见。<ref>Wittmann P, Haslbeck M, Bachmann W, Mehnert H. [Lactic acidosis in diabetics on biguanides (author's translation)] Deutsche Medizinische Wochenschrift 102(1):5-10, 1977</ref><ref>Berger W, Mehnert-Aner S, Mülly K, Heierli C, Ritz R. [10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)]. Schweizerische medizinische Wochenschrift. 106:1830-1834, 1976</ref><ref name=Deppermann>{{cite journal | author = Deppermann D, Heidland A, Ritz E, Hörl W | title = [Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)] | journal = Klin Wochenschr | volume = 56 | issue = 17 | pages = 843–53 | year = 1978 | pmid = 713413}}</ref>

==抗癌作用==
盐酸丁二胍和[[二甲双胍|二甲双胍]]还有[[苯乙双胍|苯乙双胍]]一样，抑制癌细胞生长和发育<ref>Sakae Saito, Aki Furuno, Junko Sakurai, Asami Sakamoto, Hae-Ryong Park, Kazuo Shin-ya, Takashi Tsuruo, and Akihiro Tomida. Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation. Cancer Research 2009;69(10):4225–34</ref><ref>Vladimir N. Anisimov. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Experimental Gerontology
Volume 38, Issue 10, October 2003, Pages 1041-1049</ref><ref>Valery A. Alexandrov, Vladimir N. Anisimov, Natalia M. Belous, Inna A. Vasilyeva and Vera B. Mazon. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis Volume 1, Issue 12 Pp. 975-978, 1980</ref><ref>Anisimov VN, Ostroumova MN, Dil'man VM. Inhibition of the blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female rats by buformin, diphenin, a polypeptide pineal extract and L-DOPA. Bulletin of Experimental Biology and Medicine. Volume 89, Number 6, 819-822, 1980</ref><ref>Vladimir N. Anisimov, Lev M. Berstein, Irina G. Popovich, Mark A. Zabezhinski, Peter A. Egormin, Margarita L. Tyndyk, Ivan V. Anikin, Anna V. Semenchenko, Anatoli I. Yashin. Central and Peripheral Effects of Insulin/IGF-1 Signaling in Aging and Cancer: Antidiabetic Drugs as Geroprotectors and Anticarcinogens. Annals of the New York Academy of Sciences. 1057:220-234, 2005</ref>。其抗癌机制是由于其可以阻断[[瓦氏效应|瓦氏效应]]，并且将癌细胞的供能途径从细胞基质糖解逆转回依靠线粒体的丙酮酸途径。<ref>Matthew G. Vander Heiden, Lewis C. Cantley, and Craig B. Thompson. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324 (5930): 1029-1033, 2009.</ref> <ref>Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005 Dec 9;310(5754):1642-6.</ref>

==参考文献==
{{reflist}}

{{口服降糖药和胰岛素类似物}}
[[Category:胍|Category:胍]]
[[Category:糖尿病藥物|Category:糖尿病藥物]]